InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
WinSanTorâs mission is simple-develop a drug that works. We recognize that there...
WinSanTorâs mission is simple-develop a drug ...
Establishment Labs is a global medical technology company focused on improving pat...
Establishment Labs is a global medical technolo...
Crinetics is a clinical stage pharmaceutical company focused on the discovery, dev...
Crinetics is a clinical stage pharmaceutical co...
DarĂŠ Bioscience is a clinical-stage biopharmaceutical company committed to the ad...
DarĂŠ Bioscience is a clinical-stage biopharmac...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company ...
Iterum Therapeutics plc is an Ireland-based cli...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
PhorMed is a clinical stage biopharmaceutical company located in Beverly Hills Cal...
PhorMed is a clinical stage biopharmaceutical c...
Join the National Investor Network and get the latest information with your interests in mind.